Intra-arterial delivery of bevacizumab after blood-brain barrier disruption for the treatment of recurrent glioblastoma: progression-free survival and overall survival.

@article{Burkhardt2012IntraarterialDO,
  title={Intra-arterial delivery of bevacizumab after blood-brain barrier disruption for the treatment of recurrent glioblastoma: progression-free survival and overall survival.},
  author={Jan-Karl Burkhardt and Howard Riina and Benjamin J. Shin and Paul J. Christos and K Kesavabhotla and Christoph Hofstetter and A. John Tsiouris and J A Boockvar},
  journal={World neurosurgery},
  year={2012},
  volume={77 1},
  pages={130-4}
}
BACKGROUND This prospective, single-center study assesses progression-free survival (PFS) and overall survival (OS) in patients with recurrent glioblastoma multiforme (GBM) treated with a single dose of superselective intra-arterial cerebral infusion (SIACI) of bevacizumab (BV) after blood-brain barrier disruption (BBBD). Patients were initially enrolled in our phase I study, for which the primary end point was to determine the safety and maximum tolerated dose of SIACI BV. METHODS Fourteen… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 24 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 19 references

Effectsof radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study : 5 - year analysis of the EORTCNCIC trial

  • K Belanger, P Hau, +11 authors JG Cairncross
  • Lancet Oncol
  • 2010

Phase II trial of bevacizumab and irinotecan in recurrentmalignant glioma

  • DesjardinsA VredenburghJJ, JM Dowell, +8 authors HS Friedman
  • Clin Cancer Res
  • 2009

Progression - free survival : an important endpoint in evaluating therapy for recurrenthighgrade gliomas

  • KR Lamborn, WK Yung, +16 authors Prados
  • NeuroOncol
  • 2009

Similar Papers

Loading similar papers…